larg line mse outlook move
lower compani announc heart panel date april
slightli behind expect time pt
quarter larg line estim net
revenu vs mse gross profit vs mse gross margin
vs mse opex vs mse lung revenu
strongest among organ ww lung revenu vs mse
compani end year us lung center continu focu
deeper penetr across center versu open new account
direct support
dissect guidanc revenu guidanc
lower model contribut factor varianc
includ flatter expect lung trajectori delay heart indic
approv approv could slip versu previous expect
time-frame modest coronaviru impact asia europ
ex us revenu mix lighter previou model
reflect compani focu us versu ex us reimburs
remain obstacl manag expect opex grow y/i
commentari continu suggest profit break-even run-
rate annual revenu model suggest break-even occur given
updat assum compani rais equiti financ later
detail review model chang see exhibit
heart panel time unveil compani announc fda heart
advisori panel held april postpon origin
expect revis time remain focus
import long term data given comparison data
show wider spread mortal oc control said longer
term expand data beyond import consider
rel issu remain construct
upcom catalyst span organ type includ april heart panel
potenti approv discuss liver pma submiss
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
earlier origin time-frame liver protect readout
may american transplant congress two hh
initi aim drive better util donor organ
remain equal-weight pt thesi continu rest risk-adjust
penetr multibillion dollar market expand pathway
potenti posit clinic data regulatori catalyst given earli
stage commerci launch number upcom clinic regulatori
catalyst see exist valuat offer balanc pictur
signific opportun risk adopt curv expect
remain street given slower revenu ramp increas
expect invest lower pt prior support
dcf model assum penetr lung heart
penetr liver termin oper margin wacc impli
ev sale multipl repres discount smid cap peer set
transmed risk reward driven catalyst path potenti expans
price target base dcf model wacc
ww penetr oc lung heart reect multipl base case
sale discount high growth smid cap peer
transmed oc paradigm chang
technolog allow market expans
sub-optimal organ donor pool extend
organ viabl transplant time pre-
screen organ function decreas
us heart/lung market
intermedi term oc grow transplant
volum lsd-msd annual
revenu growth driven oc
lung/heart limit contribut
view descript risk reward theme
oc momentum inect faster sale
revis higher multipl expand
oc lung heart adopt acceler
fda approv data
inspir heart expand prove
compel expans increas
lsd-msd msd-hsd penetr
increas pt us lung
us heart oc us liver
adopt acceler doubl
investor give credit liver given
oc potenti reden organ
transplant potenti improv
outcom cost econom suppli
adopt standard criteria lung drive
growth adopt expand
criteria lung drive adopt
oc heart adopt standard
expand criteria heart drive adopt
switch commerci take longer
expect upcom clinic data point
less compel limit regulatori
approv adopt oc drive
increas volum penetr
decreas pt us lung
us heart us liver
adopt delay clinic trial fall
valuat multipl contract
still recogn growth potenti
data trial demonstr improv
outcom better cost econom vs
standard care drive increas physician
everi bp ww oc heart lung
combin penetr estim dcf
china india
view explan region hierarchi
channel develop occur faster pace
lead greater oc penetr
trial data meaning posit
channel develop occur slower pace
limit physician adopt oc
fda heart panel posit delay oc
reimburs limit util
data key trial meaning wors
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
sale
sale
sale
sale
equival
st debt current portion lt debt
net chang work capit
purchas market secur
proce sale matur market secur
net invest
chg short-term debt
chg long-term debt
chang equiti
effect exchang rate chang
net financ
begin period
end period
